SPOTLIGHT -
EP. 1: Why Practitioners Should Not Overlook CINV
EP. 2: Understanding Chemotherapy-Induced Nausea and Vomiting
EP. 3: CINV: Who Is at Risk?
EP. 4: Patient Assessment Tools for CINV
EP. 5: Optimal Use of 5-HT3 Antagonists in CINV
EP. 6: Managing Side Effects with Antiemetics
EP. 7: CINV: The Role of NK1 Receptor Antagonists
EP. 8: CINV: Newer Options for Prophylaxis and Treatment
EP. 9: Understanding the Guidelines for Anti-Emetics in CINV
EP. 10: Emesis Potential of Newer Anti-Cancer Therapies
EP. 11: Unmet Needs in CINV Treatment
EP. 12: Options in Breakthrough Nausea and Vomiting
EP. 13: Emerging Approaches in CINV
EP. 14: Optimizing Care to Avoid CINV
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
